ViiV Healthcare, global specialist HIV company owned by GlaxoSmithKline (GSK), has announced an exclusive collaboration with Shionogi & Co Ltd (Shionogi) to develop a third-generation HIV integrase inhibitor (INSTI), with potential for ultra-long-acting dosing intervals.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.